Oncology News: Onyx and Eli Lilly | Market Check-Up, 8/15/13 | The Motley Fool

TL;DR

Amgen may acquire Onyx Pharmaceuticals, Eli Lilly sees positive lung cancer trial results.

Transcript

today we're taking a look at the week's biggest oncology headlines this is your market checkup now max we had a pair of big headlines this week for oncology drugs and the companies that make them let's start with onyx pharmaceuticals which has a little bit of drama going on that they rebuffed an offer from amgen then it looks like they may have agr... Read More

Key Insights

• 🥹 Onyx Pharmaceuticals holds valuable oncology assets like Capralis and potential blockbuster drugs.
• 🤨 Astrazeneca's interest in acquiring Onyx raises doubts due to their minimal focus on oncology.
• 🤞 Eli Lilly's positive phase three trial results for nesatumamab in lung cancer offer hope for future drug approvals.
• 🎟️ Bristol Myers Squibb's cancelation of their partnership with Eli Lilly may have been a missed opportunity.
• ❓ Investors should consider the impact of Cymbalta's patent expiration on Eli Lilly's revenue.
• ❓ Eli Lilly's upcoming FDA approval filings indicate a positive outlook for their drug pipeline.
• ❓ Onyx Pharmaceuticals' potential acquisition by Amgen may impact the oncology drug market significantly.

Questions & Answers

Q: Why did Onyx Pharmaceuticals reject an offer from Amgen?

Onyx Pharmaceuticals initially rebuffed Amgen's offer but may finalize a deal at $130 a share, pending clinical trial data review.

Q: Does Astrazeneca seem like a suitable fit for acquiring Onyx Pharmaceuticals?

Astrazeneca's lack of focus on oncology and previous acquisitions in other areas make their potential acquisition of Onyx questionable.

Q: Why did Bristol Myers Squibb cancel its partnership with Eli Lilly for nesatumamab?

Bristol Myers Squibb ended the partnership, leading to surprising positive phase three trial results for Eli Lilly's nesatumamab in lung cancer.

Q: How will Eli Lilly's upcoming FDA approval filing impact its current patent situation?

With a top-selling drug like Cymbalta facing patent expiration, FDA approval for new drugs like nesatumamab is crucial for Eli Lilly's revenue stability.

Summary & Key Takeaways

• Onyx Pharmaceuticals may be acquired by Amgen, offering valuable oncology assets like Capralis and royalties from other drugs.

• Astrazeneca's potential acquisition of Onyx seems questionable due to lack of focus in oncology.

• Eli Lilly's positive phase three trial results for nesatumamab in lung cancer show promise for future drug approvals.